Arcutis Biotherapeutics, Inc. ARQT Topical roflumilast program costs — R&D
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Arcutis Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Arcutis Biotherapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arcutis Biotherapeutics, Inc.'s topical roflumilast program costs — r&d.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arcutis Biotherapeutics, Inc.'s topical roflumilast program costs — R&D?
- Arcutis Biotherapeutics, Inc. (ARQT) reported topical roflumilast program costs — R&D of $3.31M in Q1 2026.
- How has Arcutis Biotherapeutics, Inc.'s topical roflumilast program costs — R&D changed year-over-year?
- Arcutis Biotherapeutics, Inc.'s topical roflumilast program costs — R&D increased by 128.7% year-over-year, from $1.45M to $3.31M.
- What is the long-term trend for Arcutis Biotherapeutics, Inc.'s topical roflumilast program costs — R&D?
- Over 2 years (2022 to 2025), Arcutis Biotherapeutics, Inc.'s topical roflumilast program costs — R&D has grown at a -63.7% compound annual growth rate (CAGR), from $83.03M to $10.94M.
- What does topical roflumilast program costs — R&D mean?
- This metric represents the direct research and development expenditures specifically allocated to the topical roflumilast product pipeline. It captures the costs associated with clinical trials, regulatory filings, and formulation development required to advance this specific therapeutic candidate toward commercialization. Monitoring these costs helps investors assess the capital intensity and progress of the company's primary dermatological asset.